Mallinckrodt Announces Specialty Brands Investor Briefing

STAINES-UPON-THAMES, United Kingdom, July 5, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced it will hold an Investor Briefing focused on its Specialty Brands pipeline development assets and commercial portfolio. The Investor Briefing takes place from 9:30 a.m. to 6 p.m., Eastern Time, on Wednesday, Oct. 4, 2017, at the Sheraton Times Square, 811 7th Ave., New York.

The briefing will begin with scientific and health economic poster presentations, product demonstrations and lunch, followed by presentations by company leaders and special guests focused on key products and research activities. The day ends with a brief reception.

Event registration is required, with attendance limited to those who register in advance. Registration can be completed here.

For those unable to attend in person, a live webcast and video of the briefing presentations will begin at noon and conclude at 5:30 p.m. Eastern Time, and will be made available at www.mallinckrodt.com/investors, where a replay of the presentations and the presentation materials also can be found after the briefing.

ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS
Investor Relations      
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
[email protected]

Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
[email protected]

Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
[email protected]

Meredith Fischer
Chief Public Affairs Officer
314-654-3318
[email protected]

SOURCE Mallinckrodt Pharmaceuticals

Related Links

http://www.mallinckrodt.com